[HTML][HTML] Molecular Pharmacology of Vitamin C and Relevance to Health and Obesity—A Narrative Review

RB Wilson, Y Liang, D Kaushal, A Carr - International journal of molecular …, 2024 - mdpi.com
The role of food constituents as pharmacological agents is an important consideration in
health and obesity. Vitamin C acts as a small molecule antioxidant but is also a co-factor for …

Inflammatory liver diseases and susceptibility to sepsis

H Lu - Clinical Science, 2024 - portlandpress.com
Patients with inflammatory liver diseases, particularly alcohol-associated liver disease and
metabolic dysfunction-associated fatty liver disease (MAFLD), have higher incidence of …

From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences

AM Samy, MA Kandeil, D Sabry, AA Abdel-Ghany… - Heliyon, 2024 - cell.com
Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent chronic liver
diseases worldwide in recent decades. Metabolic diseases like excessive blood glucose …

Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction

WPDW Thilakarathna, HPV Rupasinghe - Molecules, 2024 - mdpi.com
Nonalcoholic fatty liver disease (NAFLD), the most common liver disease worldwide, is a
spectrum of liver abnormalities ranging from steatosis to nonalcoholic steatohepatitis …

[HTML][HTML] Efficacy and Safety of Aldafermin in Non-Alcoholic Steatohepatitis: A systematic review and meta-analysis of randomized controlled trials

MM Marey, M Belal, AA Awad, EM Rabea… - Clinics and Research in …, 2024 - Elsevier
Background Non-alcoholic steatohepatitis (NASH) is an advanced subtype of non-alcoholic
fatty liver disease (NAFLD). NASH prevalence is increasing exponentially and carries a high …

[PDF][PDF] Clinics and Research in Hepatology and Gastroenterology

MM Marey, M Belal, AA Awad - researchgate.net
Background: Non-alcoholic steatohepatitis (NASH) is an advanced subtype of non-alcoholic
fatty liver disease (NAFLD). NASH prevalence is increasing exponentially and carries a high …

[HTML][HTML] Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping

S Habib - World Journal of Gastrointestinal Pathophysiology, 2024 - ncbi.nlm.nih.gov
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread global
disease with significant health burden. Unhealthy lifestyle, obesity, diabetes mellitus (DM) …

[引用][C] Liver hypercortisolism as a potential target for MASH treatment—Authors' reply

Y Kim, I Hwang, SW Lee - Alimentary Pharmacology & …, 2023 - Wiley Online Library
Editorial: Liver hypercortisolism as a potential target for MASH treatment—Authors' reply
Page 1 1240 | wileyonlinelibrary.com/journal/apt Aliment Pharmacol Ther. 2023;58:1240–1241 …